Panayiotis S Savvides MD

Oncology•Phoenix, AZ

Associate Professor, Internal Medicine, Ohio State University College of Medicine

Join to View Full Profile

625 N 6th StPhoenix, AZ 85004
Phone+1 602-406-8222

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2003
Mount Auburn HospitalResidency, Internal Medicine, 2000 - 2002
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
University of AthensClass of 1986

Certifications & Licensure

HI State Medical License 2024 - 2026
AZ State Medical License 2015 - 2025
CO State Medical License 2024 - 2025
OH State Medical License 2003 - 2016
MA State Medical License 2001 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 1
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer Start of enrollment: 2003 Feb 01
Completed
Phase 2
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer Start of enrollment: 2003 Nov 01
Terminated
Phase 1, Phase 2
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma Start of enrollment: 2004 Dec 01
Withdrawn
Not Applicable
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors Start of enrollment: 2005 Nov 01
Completed
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 3
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2007 Nov 19
COMPLETED
PHASE2
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors Start of enrollment: 2007 Aug 16
Completed
Phase 1
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck Start of enrollment: 2011 Jan 01
Terminated
Phase 2
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) Start of enrollment: 2011 Aug 01
Terminated
Phase 1, Phase 2
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2014 Apr 14
Completed
Phase 1
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Start of enrollment: 2021 Jul 23
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.
Athanassios Argiris, Yael Flamand, Panayiotis Savvides, Jennifer M Johnson, Ioannis Vathiotis
European Journal of Cancer. 2024-03-01
Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary center.
Chadi N Abdel-Halim, Thomas J O'Byrne, Jeffrey P Graves, Christeebella O Akpala, Eric J Moore
Oral Oncology. 2023-11-01
18 citations
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
Nathan Y Yu, Todd A DeWees, Molly M Voss, William G Breen, Jennifer S Chiang
Clinical Lung Cancer. 2022-12-01

Press Mentions

OncLive® Presents Seven State of the Science Summit™ Meetings in MarchFebruary 26th, 2020

Grant Support

OSI-774 + Docetaxel + Radiation In Locally Advanced Head/Neck CancerNational Center For Research Resources2005–2006
Osi-774+Docetaxel+Radiation In Locally Advanced Squamous Cell Head/Neck CancerNational Center For Research Resources2004

Panayiotis S Savvides MD

Dr. Savvides is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.